Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
|
31056731 |
2019 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy.
|
29478127 |
2018 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The BRAF mutation and primary rectal cancer were associated with poor prognostic metastatic sites.
|
30035653 |
2018 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
|
29362371 |
2018 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with right colon cancer showed more mutated BRAF (39.1% vs. 5.4%), mutated PIK3CA (13% vs. 1.4%), poorly differentiated tumor (17.4% vs. 3.4%), and peritoneal involvement (26.1% vs. 8.8%) than those with left colon and rectal cancer.
|
29169325 |
2017 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAF<sup>V600E</sup> and MET amplification.
|
28654634 |
2017 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer.
|
28801584 |
2017 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results in a population setting confirm our understanding that BRAF MT is more frequently right sided and of lower frequency in rectal cancer.
|
26714964 |
2016 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CRC primaries had a lower incidence of PIK3CA and BRAF mutations in rectal cancer versus colon cancer (10% and 3.3%, respectively).
|
26553611 |
2015 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we report a patient with rectal cancer who carried the novel BRAF mutation VK600-601E, which has analogous molecular functions to those of the conventional BRAF mutation V600E, and may have potential as a prognostic marker for colorectal cancer (CRC).
|
25636897 |
2015 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall survival; 5 years: 62.3% vs 51.6%, P=0.014; HR 1.43, CI 1.07-1.90, P=0.009), especially in rectal cancer (for DSS, HR: 10.60, CI: 3.04-36.92, P<0.001).
|
25973534 |
2015 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using a database of 735 colon and rectal cancers in the Nurse's Health Study and the Health Professionals Follow-up Study, we examined the relationship of tumor SMO expression (assessed by immunohistochemistry) to prognosis, and to clinical, pathological, and tumor molecular features, including mutations of KRAS, BRAF, and PIK3CA, microsatellite instability, CpG island methylator phenotype (CIMP), LINE-1 methylation, and expression of phosphorylated AKT and CTNNB1.
|
25023548 |
2014 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Stage III and IV colon and rectal cancers share similar molecular profiles, except that there were significantly more BRAF mutations in colon cancers compared with rectal cancers.
|
23592171 |
2013 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The predictive and prognostic value of the KRAS and BRAF point mutations as well as PTEN expression in patients with locally advanced rectal cancer (LARC) treated with cetuximab-based neoadjuvant chemoradiotherapy is unknown.
|
20947270 |
2011 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the mRNA expression of the four members of the HER family as well as the frequency of PTEN allelic loss and KRAS/BRAF mutations were determined in pretreatment biopsies from a series of 100 locally advanced rectal cancers and then their ability to predict distant metastases was evaluated.
|
20824716 |
2011 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to explore the relationships of KRAS and BRAF mutation status with p-AKT and p-ERK and outcomes in RC.
|
21910869 |
2011 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.
|
19913317 |
2010 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA, KRAS, and BRAF mutations were identified in 19 (7.9%), 81 (33.9%), and 5 (2.1%) rectal cancers.
|
19903786 |
2009 |